Videos

Ulka N. Vaishampayan, MBBS, FAB, discusses the updated data from CheckMate 214 of nivolumab and ipilimumab versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

Nicholas Rohs, MD, of Mount Sinai Hospital discusses the importance of genetic testing in lung cancers that harbor KRAS and EGFR mutations.

Marcia Brose, MD, PhD discusses the key unanswered questions oncologists have for treating patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer.

Jeff Patton, MD, explains the importance of preparedness in community oncology clinics as a World Cancer Day note.

Ken Kato, MD discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.

Brendon Stiles, MD, discusses the current landscape for treating patients with metastatic lung cancer.

Final analysis of data on HER2-positive disease presented at the 2020 San Antonio Breast Cancer Symposium from experts in the field of breast oncology.

Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.

Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.

Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.

Danielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.

Luis E. Raez, MD, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.

Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.

Analysis from the ALTTO (BIG 2-06) trial and the relationship between a short or long disease-free interval and overall survival.

Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.

Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.

A discussion on the importance of prognostic tools for early stage breast cancer.

Hatem Soliman, MD, discusses data presented at the 2020 SABCS for patients with HER2-enriched subtypes that showed benefit from CDK4/6 inhibition.

Andrew Seidman, MD, provides insight on clinical sequencing for patients with advanced HER2-positive breast cancer.

Experts in breast oncology discuss the evolving landscape in early stage and metastatic HER2-positive breast cancer.

Zev A. Wainberg, MD, discusses the impact of the COVID-19 on the colorectal cancer field specifically in terms of clinical trial research.

John L. Marshall, MD, discusses factors to consider when prescribing third line therapy for colorectal cancer in a discussion with Targeted Oncology.

Tanios S. Bekaii-Saab, MD, discusses genetic testing and emerging precision medicine strategies in the field of colorectal cancer.

Ecaterina E. Ileana Dumbrava, MD, provides background information on a phase 1/2 study of the agent alone and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors.

Halle Moore, MD, discusses the results of the IBIS-II DCIS trial of anastrozole versus tamoxifen after 12 years of follow-up for postmenopausal patients with locally excised ductal carcinoma in situ.

Sagar Lonial, MD, FACP, summarizes current challenges and his hopes for the future concerning the treatment of multiple myeloma.

Sagar Lonial, MD, FACP, focuses on the treatment of multiple myeloma during the COVID-19 pandemic, discussing the standard of care with anti-CD38 monoclonal antibodies and daratumumab.

Sagar Lonial, MD, FACP, explains the importance of daratumumab/lenalidomide/low-dose dexamethasone (DRd) in several key areas, including progression-free survival versus common standard-of-care regimens in the PEGASUS trial, toxicities, and how active patients fare.